Aimee Doyle

Aimee Doyle

Auto-generated profile, based on publicly available information

Aimee Doyle

Marie Curie Hospice Liverpool, Clatterbridge Cancer Centre, Liverpool University Hospitals NHS Foundation Trust, Merseycare

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 December 2020 in BMJ Supportive & Palliative Care
Verified
Journal Article
Closed access
PDF file
ADAimee Doyle
Aimee Doyle
MSManohar Lal Sharma
Manohar Lal Sharma
MGManish Gupta
Manish Gupta
AGAndreas Goebel
Andreas Goebel
KMKate Marley
Kate Marley
Background Percutaneous cervical cordotomy (PCC) offers pain relief to patients with unilateral treatment-refractory cancer-related pain. There is insufficient evidence about any effects of this intervention on patients’ quality of life. Method Comprehensive multimodal assessment to determine how PCC affects pain, analgesic intake and quality of life of patients with medically refractory, unilateral cancer-related pain.This study was set in a multidisciplinary, tertiary cancer pain service. Patient outcomes immediately following PCC were prospectively recorded. Patients were also followed up at 4 weeks. Results Outcome variables collected included: background and breakthrough pain numerical rating scores before PCC, at discharge and 4 weeks postprocedure; oral morphine equivalent opioid dose changes, Patient’s Global Impression of Change, Eastern Cooperative oncology group performance status and health related quality of life score, that is, EuroQol-5 dimension-5 level (EQ-5D). Conclusions Despite significant improvement in pain and other standard outcomes sustained at 4 weeks, there was little evidence of improvement in EQ-5D scores. In patients with terminal cancer, improved pain levels following cordotomy for cancer-related pain does not appear to translate into improvements in overall quality of life as assessed with the generic EQ-5D measure.

20 March 2022
Verified
Conference Paper
Open access
PDF file
PSPenny Shepherd
Penny Shepherd
ADAimee Doyle
Aimee Doyle
JRJonathan Russell
Jonathan Russell
SBSinead Benson
Sinead Benson
ADAndrew Dickman
Andrew Dickman
LCLaura Chapman
Laura Chapman
Background Ketamine is a potential adjuvant analgesic in palliative care patients with refractory pain. Regional guidance from 2012 recommends a ‘burst’ regimen with rapidly escalating doses over 5 days via continuous subcutaneous infusion (CSCI). Aim To identify current evidence for ketamine as an analgesic in palliative care in order to update regional guidance. Methods A systematic review of the literature was performed in April 2021 using electronic searches of Medline, Embase, Cinahl and Cochrane. Studies were assessed against agreed criteria by at least two independent reviewers. In parallel a case-note audit of palliative patients treated with ketamine was completed across multiple settings between August – October 2021 examining current practice against the 2012 standards and guidance. Results The case-note audit of 77 patients revealed 48.5% received burst ketamine, 27.9% oral ketamine and 23.5% lower-dose CSCI ketamine. In the literature review ten studies were accepted after full text review: two randomised controlled trials (RCT), seven observational studies and the 2017 Cochrane review ‘Ketamine as an adjuvant to opioids for cancer pain’. All included studies focused on cancer pain and were of mixed methods and quality with mixed results. A 2012 RCT of burst ketamine in 185 patients did not show any benefit over placebo and demonstrated an increased rate of adverse events. Concern over the possible lack of clinical benefit with potential for harm with a burst regimen was also highlighted in the 2017 Cochrane review. Conclusions Burst regimens of ketamine are widely used in the region. Current evidence in this area is limited, but no longer supports recommending burst regimens with rapidly escalating doses. These findings have been presented regionally and will inform the update of the new guideline. This process highlights the regenerative potential of regional audit networks in helping to keep clinical practice up to date, evidence-based and consistent.